NCT06564441View on ClinicalTrials.gov

A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

January 5, 2026

Study Completion Date

January 5, 2026

Conditions
OverweightObesity
Interventions
DRUG

Survodutide

Survodutide

DRUG

Bupropion

Bupropion

DRUG

Caffeine

Caffeine

DRUG

Midazolam

Midazolam

Trial Locations (1)

2650

SGS Life Science Services - Clinical Research, Edegem

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06564441 - A Study to Test Whether BI 456906 (Survodutide) Influences the Amount of Bupropion, Caffeine and Midazolam in the Blood in People With Overweight or Obesity | Biotech Hunter | Biotech Hunter